Aib substitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
== Solids == Many salts and solids can be dried using heat, or under vacuum. Desiccators can also be used to store reagents in dry conditions. Common desiccants include phosphorus pentoxide and silica gel. Chemists may also require dry glassware for sensitive reactions. This can be achieved by drying glassware in an oven, by flame, or under vacuum. Dry solids can be produced by freeze-drying, which is also known as lyophilization.
== Sources == Espy, Richard (1981). The Politics of the Olympic Games: With an Epilogue, 1976–1980. University of California Press. ISBN 9780520043954. Retrieved 16 June 2013. Honey, Andrew (2000). "South Africa and the Olympic Movement" (PDF). In K.B. Wamsley; S.G. Martyn; G. H. MacDonald; R.K. Barney (eds.). Bridging Three Centuries: Intellectual Crossroads and the Modern Olympic Movement. International Symposium for Olympic Research. pp. 177–184. Retrieved 17 June 2013. Killanin, Michael Morris, Lord (1983). "V: South Africa". My Olympic Years. New York: Morrow. pp. 33–45. ISBN 978-0-688-02209-9 – via Internet Archive. Ramsamy, Sam (1991). "Apartheid and Olympism: on the Abolishment of Institutionalized Discrimination in International Sport". In Fernand Landry; Marc Landry; Magdeleine Yerlès (eds.). Sport, the Third Millennium: Proceedings of the International Symposium, Quebec City, Canada, May 21-25, 1990. Presses Université Laval. pp. 539–548. ISBN 9782763772677. Retrieved 17 June 2013.
target site The site or locus upon another molecule at which a protein performs a particular biochemical activity; e.g. the nucleotide motif at which a restriction endonuclease cleaves a DNA molecule, often but not necessarily the same as the enzyme's recognition site (i.e. a restriction enzyme may recognize one motif, known as a restriction site, and cleave at another).
Sources: en.wikipedia.org
== Selected publications == Bounous, G; Molson, JH (2003). "The antioxidant system". Anticancer Research. 23 (2B): 1411–5. PMID 12820403. Kennedy, RS; Konok, GP; Bounous, G; Baruchel, S; Lee, TD (1995). "The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: A phase I-II clinical study". Anticancer Research. 15 (6B): 2643–9. PMID 8669840. Bounous, Gustavo; Somersall, Allan (April 1999). Breakthrough In Cell-Defense. GOLDENeight Publishing. ISBN 978-1-890412-86-9.
It is rare to find less than five interacting parallel strands in a motif, suggesting that a smaller number of strands may be unstable, however it is also fundamentally more difficult for parallel β-sheets to form because strands with N and C termini aligned necessarily must be very distant in sequence . There is also evidence that parallel β-sheet may be more stable since small amyloidogenic sequences appear to generally aggregate into β-sheet fibrils composed of primarily parallel β-sheet strands, where one would expect anti-parallel fibrils if anti-parallel were more stable. In parallel β-sheet structure, if two atoms Cαi and Cαj are adjacent in two hydrogen-bonded β-strands, then they do not hydrogen bond to each other; rather, one residue forms hydrogen bonds to the residues that flank the other (but not vice versa). For example, residue i may form hydrogen bonds to residues j − 1 and j + 1; this is known as a wide pair of hydrogen bonds. By contrast, residue j may hydrogen-bond to different residues altogether, or to none at all. The hydrogen bond arrangement in parallel beta sheet resembles that in an amide ring motif with 11 atoms. Finally, an individual strand may exhibit a mixed bonding pattern, with a parallel strand on one side and an antiparallel strand on the other.
The Byzantine-Ottoman wars and the Ottoman wars in Europe brought large numbers of slaves into the Islamic world. To staff its bureaucracy, the Ottoman Empire established a janissary system which seized hundreds of thousands of Christian boys through the devşirme system. They were well cared for but were legally slaves owned by the government and were not allowed to marry. They were never bought or sold. The empire gave them significant administrative and military roles. The system began about 1365; there were 135,000 janissaries in 1826, when the system ended. After the Battle of Lepanto, 12,000 Christian galley slaves were recaptured and freed from the Ottoman fleet. Eastern Europe suffered a series of Tatar invasions, the goal of which was to loot and capture slaves for selling them to Ottomans as jasyr. Seventy-five Crimean Tatar raids were recorded into Poland–Lithuania between 1474 and 1569. Romani people were enslaved in Romania. It was the longest chattel slavery in Europe.
Stroganoff is also popular in Nordic countries. In Sweden, a common variant is Korv stroganoff (lit. 'sausage stroganoff'), which traditionally uses the local falukorv sausage as a substitute for the beef. In Finland, the dish is called makkarastroganoff (lit. 'sausage stroganoff'). Beef Stroganoff is, however, also a common dish in Finland. Diced brined pickles are also a normal ingredient in Finnish Stroganoff.
Sources: en.wikipedia.org
The rate of proteolysis may also depend on the physiological state of the organism, such as its hormonal state as well as nutritional status. In time of starvation, the rate of protein degradation increases.
== Management == As of July 2025, there are no clear guidelines for treating Type 5 diabetes. Some evidence suggests that very small amounts of insulin combined with oral medications may be most effective. It is crucial to differentiate Type 5 diabetes from Type 1 diabetes, as administering too much insulin can quickly be fatal. The diet for patients should include significantly higher amounts of protein and fewer carbohydrates, with special attention paid to correcting micronutrient deficiencies.
In the six years since the Invasion of Grenada, Operation Just Cause demonstrated how quickly the US Armed Forces could adapt and overcome the mistakes and equipment interoperability issues to conduct a quick and decisive victory. In all, the 82nd Airborne Division suffered six of the 23 fatalities of the operation. The paratroopers began redeployment to Fort Bragg on 12 January 1990. Operation Just Cause concluded on 31 January 1990, 42 days (D+42) after the invasion started.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.